Abstract:Background Rheumatoid arthritis (RA) worsens patients9 health-related quality of life.1 Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of RA. Improvements in patient-reported outcomes (PROs) have been reported in the global population of Phase 3 tofacitinib trials.2 Objectives To explore the effect of tofacitinib administered with conventional synthetic DMARDs (csDMARDs) on PROs in Chinese patients with RA and an inadequate response to DMARDs. Methods This was a post-hoc analysis of data from Chinese patients in the 12 month, double-blind Phase 3 study ORAL Sync (NCT00856544), with patients randomised 4:4:1:1 to tofacitinib 5 mg BID, tofacitinib 10 mg BID, placebo (PBO)→tofacitinib 5 mg BID or PBO→tofacitinib 10 mg BID, with csDMARDs. Non-responders (defined as those who did not achieve a 20% improvement in both of the swollen or tender joint counts) receiving PBO advanced blindly to tofacitinib at Month 3; all remaining PBO patients advanced to tofacitinib at Month 6. Least squares mean changes from baseline were reported for Health Assessment Questionnaire-Disability Index (HAQ-DI), patient assessment of arthritis pain (VAS), patient global assessment of disease activity (PtGA), Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue scale, Short Form-36 Health Survey (SF-36), EuroQol five dimensions questionnaire (EQ-5D), and Work Limitations Questionnaire (WLQ), using a mixed-effects model for repeated measures. All patients receiving ≥1 dose of study treatment with ≥1 post-baseline assessment were included. Results Overall 216 patients were included (n=86, tofacitinib 5 mg BID; n=86, tofacitinib 10 mg BID; n=22, PBO→tofacitinib 5 mg BID; n=22, PBO→tofacitinib 10 mg BID). There were no major differences in demographics or baseline characteristics between treatment groups. At Month 3, tofacitinib resulted in significantly greater changes in HAQ-DI (5 mg BID, p<0.05; 10 mg BID, p<0.001), PtGA (5 mg BID, p<0.05; 10 mg BID, p<0.001), Pain (5 mg BID, p<0.001; 10 mg BID, p<0.001) and SF-36 Physical Component Summary (PCS) scores (5 mg BID, p<0.05; 10 mg BID, p<0.001) vs PBO (Figure). Numeric improvements in FACIT-Fatigue, SF-36 Mental Component Summary (MCS) [Figure] and EQ-5D health state profile (utility scores) were observed at Month 3 with tofacitinib vs PBO. There were no improvements in WLQ observed at Month 3 with tofacitinib vs PBO. Improvements were generally maintained at 6 and 12 months (Figure). The proportion of patients achieving HAQ-DI improvement ≥0.22 from baseline at Month 3 was significantly higher with tofacitinib vs PBO (5 mg BID, p<0.05; 10 mg BID, p<0.05). Conclusions Tofacitinib 5 and 10 mg BID administered with csDMARDs significantly improved PROs including SF-36 PCS, PtGA, physical function and pain vs PBO. These improvements were maintained for up to 12 months in Chinese patients with RA. References Strand V, Khanna D. Clin Exp Rheumatol 2010; 28: S32-S40. Strand V et al. Arthritis Care Res (Hoboken) 2016. doi:10.1002/acr.23004. Acknowledgements This study was sponsored by Pfizer Inc. Editorial support was provided by C Evans of CMC and was funded by Pfizer Inc. Disclosure of Interest Z. Li Grant/research support from: Pfizer Inc, Consultant for: Pfizer Inc, Y. An Grant/research support from: Pfizer Inc, Consultant for: Pfizer Inc, G. Li Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, L. Wang Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, K. Kwok Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Q. Wu Shareholder of: Pfizer Inc, Employee of: Pfizer Inc

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme

Efficacy and safety of tofacitinib in rheumatoid arthritis: Nine years of real‐world data

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

AB0514 Efficacy and Safety of Tofacitinib in Chinese Patients with Active Rheumatoid Arthritis: Subgroup Analysis from a Phase 3 Study of Tofacitinib in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs

Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study

THU0215 Effects of Tofacitinib on Patient-Reported Outcomes in a Phase 3 Study of Chinese Patients with Active Rheumatoid Arthritis and an Inadequate Response to Dmards

A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis

Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis

P760 Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: A final report of effectiveness and safety data

Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance

Multicenter evaluation of tofacitinib retention and safety in rheumatoid arthritis – why cardiovascular risk factors do not equate to overt risk